Uric acid reducing and gout resisting composition as well as preparation method and application thereof

Abstract

The invention discloses a uric acid-reducing and gout-resisting composition as well as a preparation method and application thereof. The composition capable of reducing uric acid and resisting gout comprises oligosaccharide, plant powder, yeast powder, oligopeptide and probiotic powder. The plant powder in the composition has a diuretic effect and can promote purine and uric acid to be discharged along with urine, so that the content of the uric acid is reduced; the yeast powder is introduced to promote dissolution and discharge of purine, so that the content of uric acid is reduced; probiotics are introduced, reproduction of harmful bacteria such as escherichia coli, clostridium perfringens and enterococcus is inhibited, proliferation of the probiotics is promoted, the micro-ecological environment of the intestinal tract is improved, uric acid entering the intestinal tract is decomposed through metabolism, dissolution of the uric acid is promoted, the influence of intestinal flora on uric acid excretion is reduced, and it is ensured that uric acid in the intestinal tract is excreted; the uric acid reducing and gout resisting composition disclosed by the invention has a relatively good protection effect on the liver.

Description

Technical Field

[0001] The present invention relates to the technical field of exosomes, and in particular to a uric acid-lowering and anti-gout composition and a preparation method and application thereof. Background Art

[0002] Currently, the main uric acid-lowering drugs include xanthine oxidase (XO) inhibitors, such as allopurinol and febuxostat, and drugs that promote renal uric acid excretion, such as benzbromarone and probenecid. However, existing drugs have certain safety risks. Allopurinol may cause skin allergic reactions and liver and kidney damage, febuxostat may increase the risk of sudden cardiac death and severe liver damage, and benzbromarone has the risk of fulminant hepatitis.

[0003] Currently, commonly used uric acid-lowering drugs include allopurinol, probenecid, colchicine, and nonsteroidal anti-inflammatory drugs, which dominate the market. However, these drugs have serious adverse reactions, especially long-term use will have great toxic side effects on the liver and related organs, which has limited their clinical application.

[0004] Therefore, a uric acid-lowering and anti-gout composition with no toxic side effects is developed. Summary of the invention

[0005] The purpose of the present invention is to overcome the deficiencies of the above-mentioned prior art and provide a uric acid-lowering and anti-gout composition and a preparation method and application thereof.

[0006] To achieve the above object, the technical solution adopted by the present invention is:

[0007] In the first aspect, the present invention provides a uric acid lowering and anti-gout composition, comprising the following components in parts by weight: 1 to 10 parts of oligosaccharides, 5 to 45 parts of plant powder, 0.05 to 0.5 parts of yeast powder, 0.05 to 0.1 parts of oligopeptides, and 0.05 to 0.5 parts of probiotic powder, wherein the plant powder includes at least one of cherry powder, lily powder, light bamboo leaf powder, and apple powder.

[0008] Preferably, the probiotic powder includes at least one of Lactobacillus gasseri powder, fermented Lactobacillus mucilaginosus powder, Lactobacillus mucilaginosus reuteri powder and Lactobacillus plantarum powder.

[0009] Further preferably, the probiotic powder comprises the following components in parts by weight: 0.01-0.1 parts of Lactobacillus gasseri powder, 0.01-0.1 parts of fermented Lactobacillus mucilaginosus powder, 0.01-0.1 parts of Lactobacillus reuteri powder, and 0.01-0.1 parts of Lactobacillus plantarum powder.

[0010] The inventors have found through research that the probiotics formed by the combination of Lactobacillus gasseri, Lactobacillus mucosa fermentation, Lactobacillus mucosa reuteri and Lactobacillus plantarum have excellent nucleoside and nucleotide degradation capabilities, can decompose most of the precursors of uric acid synthesis (nucleosides and nucleotides), thereby reducing the body's absorption of the precursors of uric acid synthesis, and can also directly and efficiently decompose uric acid entering the intestine, and by reducing serum endotoxin levels and inhibiting xanthine oxidase activity, thereby inhibiting the production of uric acid and relieving inflammation; the probiotics introduced by the present invention can regulate intestinal flora, inhibit the reproduction of harmful bacteria, and improve the intestinal microecological environment. Organic acids such as lactic acid and acetic acid produced by the metabolism of probiotics help to lower the pH value of the small intestine, indirectly promote the dissolution and excretion of uric acid, and reduce the formation of uric acid crystals.

[0011] The number of live bacteria of the Lactobacillus gasseri powder is 1×10 10 ~2×10 10 CFU / g, the number of viable bacteria of the fermented mucus lactobacillus powder is 1×10 10 ~2×10 10 CFU / g, the viable bacterial count of the Lactobacillus reuteri powder is 0.5×10 10 ~1×10 10 CFU / g, the number of live bacteria of the plant lactobacillus powder is 0.5×10 10 ~1×10 10 CFU / g.

[0012] More preferably, the probiotic powder comprises the following components in parts by weight: 0.02-0.04 parts of Lactobacillus gasseri powder, 0.02-0.06 parts of fermented Lactobacillus mucilaginosus powder, 0.02-0.06 parts of Lactobacillus reuteri powder, and 0.05-0.08 parts of Lactobacillus plantarum powder.

[0013] Preferably, the uric acid lowering and anti-gout composition comprises the following components in parts by weight: 4 to 8 parts of oligosaccharides, 7 to 19 parts of plant powder, 0.1 to 0.3 parts of yeast powder, 0.02 to 0.05 parts of oligopeptides, and 0.2 to 0.4 parts of probiotic powder.

[0014] Further preferably, the plant powder comprises the following components in parts by weight: 2-7 parts of cherry powder, 2-5 parts of lily powder, 2-4 parts of light bamboo leaf powder, and 1-3 parts of apple powder.

[0015] Preferably, the cherry powder is prepared by the following method: fresh cherries are washed, pitted, vacuum freeze-dried, and crushed to obtain the cherry powder.

[0016] Preferably, the lily powder is prepared by the following method: fresh lilies are washed, vacuum freeze-dried, and crushed to obtain the lily powder.

[0017] Preferably, the Bambusa chinensis leaf powder is prepared by the following method: fresh Bambusa chinensis leaves are washed, vacuum freeze-dried, and crushed to obtain Bambusa chinensis leaf powder.

[0018] Preferably, the apple powder is prepared by the following method: fresh apples are washed, peeled, cut into pieces, cored, vacuum freeze-dried, and crushed to obtain the apple powder.

[0019] Preferably, the composition further comprises the following components in parts by weight: 1 to 10 parts of yellow mustard freeze-dried powder and 1 to 10 parts of Imperata root freeze-dried powder.

[0020] Further preferably, the composition further comprises the following components in parts by weight: 1 to 5 parts of yellow mustard freeze-dried powder and 1 to 5 parts of Imperata root freeze-dried powder.

[0021] More preferably, the composition further comprises the following components in parts by weight: 2-4 parts of yellow mustard freeze-dried powder and 2-4 parts of white cypress root freeze-dried powder. The inventors have found through research that the addition of yellow mustard freeze-dried powder and white cypress root freeze-dried powder can promote the excretion of uric acid and reduce uric acid synthesis. When the addition amount of yellow mustard freeze-dried powder and white cypress root freeze-dried powder is within the above range, the composition has a better effect of reducing uric acid.

[0022] Further preferably, the yellow mustard freeze-dried powder is prepared by the following method: crushing the yellow mustard, mixing it with water and then grinding it, filtering and collecting the yellow mustard filtrate, mixing the collected yellow mustard filtrate with β-cyclodextrin, shearing and dispersing it evenly, and freeze-drying to obtain the yellow mustard freeze-dried powder; wherein the mass ratio of the yellow mustard to water is 1:(0.1~5), and the mass ratio of the yellow mustard filtrate to β-cyclodextrin is 100:(1~5).

[0023] Further preferably, the Imperata root powder is prepared by the following method: crushing the Imperata root, mixing it with water and then grinding it, collecting the Imperata root filtrate after filtering, mixing the collected Imperata root filtrate with β-cyclodextrin, shearing and dispersing it evenly, and freeze-drying to obtain the Imperata root freeze-dried powder; wherein the mass ratio of the Imperata root to water is 1:(0.1~5), and the mass ratio of the Imperata root filtrate to β-cyclodextrin is 100:(1~5).

[0024] Preferably, the oligopeptide is a marine fish oligopeptide, and more preferably a bonito oligopeptide. Bonito oligopeptide is an oligopeptide processed from a bonito extract. Bonito oligopeptide can inhibit excessive production of uric acid and promote the excretion of uric acid from the body.

[0025] Preferably, the oligosaccharide includes at least one of galacto-oligosaccharide, fructo-oligosaccharide, isomalto-oligosaccharide and xylo-oligosaccharide.

[0026] In a second aspect, the present invention provides a use of the composition as described in the first aspect in preparing a food having uric acid-lowering effect.

[0027] In the present invention, the food may be a solid beverage.

[0028] In a third aspect, the present invention provides a use of the composition as described in the first aspect in the preparation of a uric acid-lowering drug.

[0029] In a fourth aspect, the present invention provides a use of the composition as described in the first aspect in the preparation of a drug for preventing gout.

[0030] Compared with the prior art, the present invention has the following beneficial effects:

[0031] (1) The plant powder in the composition of the present invention has a diuretic effect, which can promote the excretion of purine and uric acid in urine, thereby reducing the uric acid content;

[0032] (2) The present invention promotes the dissolution and excretion of purine by introducing yeast powder, thereby reducing the uric acid content;

[0033] (3) The present invention can inhibit the reproduction of harmful bacteria such as Escherichia coli, Clostridium perfringens and Enterococcus by introducing probiotics, promote the proliferation of probiotics, improve the intestinal microecological environment, metabolize and decompose uric acid entering the intestine, promote uric acid dissolution, reduce the influence of intestinal flora on uric acid excretion, and ensure the excretion of uric acid in the intestine;

[0034] (4) The uric acid-lowering and anti-gout composition of the present invention has a good protective effect on the liver. DETAILED DESCRIPTION

[0035] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0036] The pH value of the following PBS buffer solution is 7.2;

[0037] The yeast powder described below is from French Lesaffre (company) yeast powder (rich in B vitamins) (trade name and / or model);

[0038] The following Lactobacillus gasseri powder comes from Lactobacillus gasseri LG08 (trade name and / or model) of Weikang Probiotics (Suzhou) Co., Ltd. (company), wherein the number of viable bacteria is 100 billion CFU / g;

[0039] The fermented mucus lactobacillus powder is from the fermented mucus lactobacillus (trade name and / or model) of Jinqiao Biotechnology Co., Ltd. (company), wherein the viable bacteria count is 100 billion CFU / g;

[0040] The following Lactobacillus reuteri powder comes from Lactobacillus reuteri (trade name and / or model) of Jinqiao Biotechnology Co., Ltd. (company), wherein the viable bacterial count is 100 billion CFU / g;

[0041] The following Lactobacillus plantarum powder comes from Lactobacillus plantarum (trade name and / or model) of Jinqiao Biotechnology Co., Ltd. (company), wherein the number of viable bacteria is 1000 CFU / g.

[0042] The embodiments and comparative examples of the uric acid-lowering anti-gout composition of the present invention, and the preparation method of the uric acid-lowering anti-gout composition are as follows:

[0043] S1. Wash and pit fresh cherries, put them into a freeze dryer, freeze-dry them at -30°C for 220 min, evacuate to 80 Pa, heat to 95°C, dry them at 80 Pa and 95°C for 1.5 h, crush them and pass them through a 150-mesh sieve to obtain cherry powder;

[0044] S2, washing fresh lilies, freeze-drying them at a vacuum degree of 100 Pa and a temperature of -60°C for 22 h, crushing them and passing them through a 200-mesh sieve to obtain lily powder;

[0045] S3, washing the fresh bamboo leaves, freeze-drying them at a vacuum degree of 100 Pa and a temperature of -60°C for 24 h, crushing them and passing them through a 200-mesh sieve to obtain bamboo leaf powder;

[0046] S4. Wash, peel, core and cut fresh apples into pieces, put them into a freeze dryer, freeze-dry them at -35°C for 220 min, evacuate to 80 Pa, heat to 95°C, dry them at 80 Pa and 95°C for 2 h, crush them and pass them through a 150-mesh sieve to obtain cherry powder;

[0047] S5, washing and cutting fresh apples, drying at 60° C. until the moisture content is no more than 6%, grinding, and passing through a 200-mesh sieve to obtain apple powder;

[0048] S6, crushing the dried yellow mustard seeds and adding deionized water, the mass ratio of yellow mustard seeds to deionized water is 1:0.5, grinding the mixture after mixing, collecting the yellow mustard filtrate after filtering, mixing the collected yellow mustard filtrate with β-cyclodextrin in a mass ratio of 100:1.8, shearing and dispersing the mixture evenly, and freeze-drying the mixture to obtain a yellow mustard lyophilized powder;

[0049] S7, after the dried Imperata root is crushed, deionized water is added, the mass ratio of Imperata root to deionized water is 1:0.5, the mixture is ground, the Imperata root filtrate is collected after filtration, the collected Imperata root filtrate is mixed with β-cyclodextrin in a mass ratio of 100:1.6, the mixture is sheared and dispersed evenly, and freeze-dried to obtain Imperata root freeze-dried powder;

[0050] S8. According to Tables 1-2, mix the components to obtain a composition.

[0051] Table 1

[0052]

[0053]

[0054] Table 2

[0055]

[0056]

[0057] Effect Example 1

[0058] 5-week-old male C57BL / 6J mice, SPF grade, body weight (17±1) g, were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd. and kept in the SPF environment of the animal room of Hunan Normal University (temperature 21-23°C, humidity 40-60%, light / dark photoperiod 12h), and adaptively fed for 1 week; mice with a weight difference of no more than 5g were selected and randomly divided into the experimental group, normal control group and model control group as shown in Table 3;

[0059] Experimental group and model control group: according to the standard of 300 mg potassium oxonate and 60 mg adenine per kilogram body weight, potassium oxonate solution was intraperitoneally injected and adenine was gavaged; continuous injection and gavage for three days to establish a hyperuricemia model; after the model was established, each experimental group was gavaged with the corresponding composition solution, and the model control group was gavaged with normal saline, and the dosage was 0.2 mL / mouse; the composition solution used in each experimental group was prepared by mixing the composition shown in Table 3 and normal saline, wherein the mass percentage of the composition was 4%; during the experiment, mice in each group were free to eat mouse chow and drink water.

[0060] Normal control group: The mice were allowed to eat mouse chow and drink water freely during the whole experimental period.

[0061] Test period: 5 weeks.

[0062] The feces of each mouse were collected before administration and 5 weeks after administration, and the feces were diluted 10 times as samples for the following tests:

[0063] (1) Spread 0.2 mL of the solution on eosin-methylene blue agar (EMB) and culture it anaerobically at 37°C for 48 h. Detect the number of Escherichia coli colonies by plate counting method and take the average value of the test results.

[0064] (2) Take 0.2 mL of the sample and spread it on trypticase-sulfite-cycloserine agar (TSC) medium. After anaerobically incubating at 37°C for 48 h, the number of Escherichia coli colonies was detected by plate count method, and the test results were averaged;

[0065] (3) Take 0.2 mL of the sample and spread it on enterococcal agar medium. After anaerobically incubating at 37°C for 48 h, the number of Escherichia coli colonies was detected by plate count method, and the test results were averaged;

[0066] 2 hours after the last administration, the mice were anesthetized, blood was collected from the abdominal aorta, serum was separated by centrifugation, and the supernatant was collected and stored at -40°C for later use. The uric acid content in the serum was detected by enzyme colorimetry, and the test results were averaged.

[0067] Before blood collection, weigh the mouse. After blood collection, remove the mouse liver, clean the blood, hair, etc. attached to the liver organ, dry it, weigh the wet weight of the liver and calculate the organ index, liver index (%) = wet weight of liver (g) / mouse body weight (g) * 100%, and take the average value of the results.

[0068] The test results are shown in Table 3 below.

[0069] Table 3

[0070]

[0071]

[0072]

[0073]

[0074] As can be seen from Table 3, the composition provided by the present invention can not only effectively reduce the serum uric acid content, but also effectively regulate the intestinal flora, inhibit the reproduction of harmful bacteria such as Escherichia coli, Clostridium perfringens and Enterococcus, and has a certain inhibitory effect on liver damage caused by hyperuricemia.

[0075] It can be seen from Examples 1 and 9 to 12 that the addition of lyophilized powder of yellow mustard seeds and lyophilized powder of Imperata root can significantly reduce the serum uric acid content.

[0076] It can be seen from Example 1 and Comparative Examples 1 to 2 that the combination of cherry powder, lily powder, bamboo leaf powder and apple powder can more effectively promote the excretion of purine in mice with hyperuricemia, thereby lowering the uric acid content in serum.

[0077] It can be seen from Example 1 and Comparative Examples 3 to 7 that, compared with the powder of a single strain, the present invention compounds yeast powder, Lactobacillus gasseri powder, fermented mucus Lactobacillus powder, Lactobacillus reuteri mucus powder and Lactobacillus plantarum powder, which, through synergistic effect, can more significantly inhibit the reproduction of harmful bacteria such as Escherichia coli, Clostridium perfringens and Enterococcus, and more significantly reduce the uric acid content in serum.

[0078] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A uric acid-lowering and anti-gout composition, characterized in that: The invention comprises the following components in parts by weight: 1 to 10 parts of oligosaccharides, 5 to 45 parts of plant powder, 0.05 to 0.5 parts of yeast powder, 0.05 to 0.1 parts of oligopeptides and 0.05 to 0.5 parts of probiotic powder. The plant powder comprises at least one of cherry powder, lily powder, light bamboo leaf powder and apple powder.

2. The uric acid-lowering and anti-gout composition according to claim 1, characterized in that: The probiotic powder comprises at least one of Lactobacillus gasseri powder, fermented Lactobacillus mucilaginosus powder, Lactobacillus reuteri powder and Lactobacillus plantarum powder.

3. The uric acid-lowering and anti-gout composition according to claim 2, characterized in that: The probiotic powder comprises the following components in parts by weight: 0.01-0.1 parts of Lactobacillus gasseri powder, 0.01-0.1 parts of fermented Lactobacillus mucilaginosus powder, 0.01-0.1 parts of Lactobacillus reuteri mucilaginosus powder, and 0.01-0.1 parts of Lactobacillus plantarum powder. The number of live bacteria of the Lactobacillus gasseri powder is 1×10 10 ~2×10 10 CFU / g, the number of viable bacteria of the fermented mucus lactobacillus powder is 1×10 10 ~2×10 10 CFU / g, the viable bacterial count of the Lactobacillus reuteri powder is 0.5×10 10 ~1×10 10 CFU / g, the number of live bacteria of the plant lactobacillus powder is 0.5×10 10 ~1×10 10 CFU / g.

4. The uric acid-lowering and anti-gout composition according to claim 1, characterized in that: The invention comprises the following components in parts by weight: 4-8 parts of oligosaccharides, 7-19 parts of plant powder, 0.1-0.3 parts of yeast powder, 0.02-0.05 parts of oligopeptides and 0.2-0.4 parts of probiotic powder.

5. The uric acid-lowering and anti-gout composition according to claim 1, characterized in that: The plant powder comprises the following components in parts by weight: 2-7 parts of cherry powder, 2-5 parts of lily powder, 2-4 parts of light bamboo leaf powder, and 1-3 parts of apple powder.

6. The uric acid-lowering and anti-gout composition according to claim 1, characterized in that: The oligopeptide is a marine fish oligopeptide, and the oligosaccharide comprises at least one of galacto-oligosaccharide, fructo-oligosaccharide, isomalto-oligosaccharide and xylo-oligosaccharide.

7. The uric acid-lowering anti-gout composition according to claim 1, characterized in that: The invention also comprises the following components in parts by weight: 1 to 10 parts of yellow mustard freeze-dried powder and 1 to 10 parts of Imperata root freeze-dried powder.

8. Use of the composition according to any one of claims 1 to 7 in preparing food having uric acid lowering effect.

9. Use of the composition according to any one of claims 1 to 7 in the preparation of a uric acid-lowering drug.

10. Use of the composition according to any one of claims 1 to 7 in the preparation of a medicament for preventing gout.

Images